Stem cell therapies hold great promise for diseases such as stroke, where few effective treatment options exist. Clinical translation of experimental stem cell therapies requires the ability to monitor delivery and behaviour of cells non-invasively in-vivo with clinical imaging modalities such as MRI. This thesis presents the translation of established methods for labelling and imaging stem cells with specialized MRI systems to a more clinically relevant setting. A methodology for harvesting and labelling a cell population containing stem cells with iron oxide for detection with a clinical MRI system is presented and single cell detection is demonstrated in-vitro. The feasibility of detecting iron oxide labelled stem cells intravenously delivered in a rat model of stroke is tested. Results demonstrate that while MRI is highly sensitive to the presence and distribution of iron oxide containing cells in-vivo the true origin of these cells remains ambiguous with the current methodology.

Stem cell therapies hold great promise for diseases such as stroke, where few effective treatment options exist. Clinical translation of experimental stem cell therapies requires the ability to monitor delivery and behaviour of cells non-invasively in-vivo with clinical imaging modalities such as MRI. This thesis presents the translation of established methods for labelling and imaging stem cells with specialized MRI systems to a more clinically relevant setting. A methodology for harvesting and labelling a cell population containing stem cells with iron oxide for detection with a clinical MRI system is presented and single cell detection is demonstrated in-vitro. The feasibility of detecting iron oxide labelled stem cells intravenously delivered in a rat model of stroke is tested. Results demonstrate that while MRI is highly sensitive to the presence and distribution of iron oxide containing cells in-vivo the true origin of these cells remains ambiguous with the current methodology.

<p> Aqueous ferrofluid has been prepared via precipitation of iron oxide into a polysaccharide gel matrix followed by degradation of the polymer to form a stable magnetic colloid. Nanocrystalline particles of iron oxide were formed in an alginate network by the alkaline hydrolysis and oxidation of the crosslinking agent, Fe2+, used to bind the linear polysaccharide chains. Methanol was used to inhibit the degradation of alginate by Fe2+ and oxygen during the precipitation and growth of iron oxide particles. In addition, the structural integrity of the gel was maintained in part by interaction between the iron oxide particulate and the alginate matrix. Controlled chemical degradation of the matrix resulted in a aqueous suspension of alginate-stabilized magnetic iron oxide particles. The resulting fluid is orange-brown in color, optically transparent, superparamagnetic and stable between 2.8<pH<10 </p> <p> The magnetic gels were isolated as 2mm beads containing ~2-20 mmole Fe. X-ray and electron diffraction patterns of the composite correspond to maghemite (γ-Fe2O3) and/or magnetite (Fe3O4). At room temperature, the composite material is superparamagnetic with saturation magnetizations in excess of 20 emu g^-1 at 30kOe. TEM photomicrographs of sectioned beads and of the magnetic fluid revealed the presence of spherical nanocrystalline oxide particles with diameters ranging from 3 nm to 6 nm. The iron oxide-alginate colloid has a diameter of 54nm with an average zeta potential of -51.6 mV.</p> / Thesis / Master of Science (MSc)

Development of nanostructures as MR contrast agent will significantly improve the field of disease diagnostics. Contrast agents such as iron oxide nanoparticles are less toxic compared to more commonly used gadolinium based agents. A subclass of iron based nano particles are super paramagnetic iron oxide nano particles, (SPIOs) which are widely studied MR contrast agents useful in both imaging and drug delivery applications. In this work, SPIOs were synthesized and characterized and used for cellular tracking and multi modal labeling. A new solvent exchange method was utilized to coat different core size iron oxide nano particles. SPIOs were characterized for in-vivo imaging using MR and they had a very uniform size distribution which was determine using dynamic light scattering (DLS) and transmission electron microscopy. Furthermore, blood circulation half-life of 16nm SPIOs were determined through tail vein injection. SPIOs have many applications among which is the in vivo tracking of stem cells which is critical for determination of stem cells fate after injection. Magnetic Resonance (MR) as a non-invasive method can provide significant information about the fate of the cells as well as determination of the success rate of therapeutic cellular deliveries. Mesenchymal stem cells can be loaded with super paramagnetic iron oxide nano particles (SPIOs) and have their movements followed once planted in vivo. We present our findings on the effect of SPIO concentration and stem cell density on the MR signal and transverse relaxation time. Our preliminary results indicated that SPIOs do not cause mesenchymal stem cell cytotoxicity and do not affect proliferation ability up to 200 μg/ml concentration. The release of the nanoparticles was investigated 24 hours post internalization and the result showed that SPIOs will stay inside the cell. We also found that the contrast increases in a concentration dependent manner. Our results suggest that using MR with low concentration of SPIOs is a novel and promising method for tracking of mesenchymal stem cells. In this work SPIOs were also labeled with 64Cu to investigate their potential for multi modal positron emission tomography (PET) MR imaging. Dual modality PET MR SPIO contrast agent can be synthesized to image diseases such as cancer and atherosclerosis. The advantage is the non-invasive and early detection of disease at molecular lever before it has spread to late stages or in case of the atherosclerosis before the plaque has blocked the vessel. To develop a multi modal contrast agent, a positron emitter, 64Cu (half-life of 12.701 ± 0.002 hours), was used in labeling and synthesis was performed all in one step with the addition of 64Cu chelator, 14-PE DTPA followed by radiolabeling for both 6.5nm SPIO and 17nm SPIO. After labeling and purification with the desalting column, the amount of dissociated 64Cu in the solution was determined using radio thin layer chromotagraphy (TLC) and the particle was shown to have minimum amount of fee 64Cu. Serum stability of labeled SPIO was determined in vitro by incubating 64Cu-labeled SPIOs in mouse serum at 37 °C for 24 hr with constant shaking. Radio TLC result then revealed that 64Cu stays bounded to the SPIO after 24 hours in mouse serum. This means that 64Cu labeled SPIO has a great potential as a dual modality contrast agents and further in-vivo studies are required to verify the findings.

Mesenchymale Stammzellen (MSC) werden bereits in klinischen Studien zur Behandlung verschiedener Krankheiten eingesetzt. Über deren Wirkmechanismus und Verbleib nach Applikation ist jedoch noch wenig bekannt. Die in vivo-Nachverfolgung markierter MSC mittels Magnetresonanztomographie stellt eine mögliche Methode zur Erlangung weiterer Erkenntnisse dar. Zu diesem Zweck können die MSC mittels superparamagnetischen Eisenoxid (SPIO)-Partikeln markiert werden. In dieser Arbeit wurden 3 verschiedene SPIO-Produkte zur Markierung oviner und equiner MSC verwendet: Endorem™, Resovist® und Molday ION Rhodamine B™. Die Produkte wurden hinsichtlich ihrer Einflüsse auf die biologischen Eigenschaften der MSC, ihrer Markierungseffizienz und –selektivität verglichen. Desweiteren wurde die produktspezifische magnetresonanztomographische Nachverfolgbarkeit der SPIO-markierten MSC untersucht. Weiterführendes Ziel war die Selektion des am besten geeigneten SPIO-Produktes für die Verwendung in einem in vivo-Großtierversuch zur magnetresonanztomographischen Nachverfolgung SPIO-markierter MSC nach Applikation in arthrotische Gelenke. Die MSC wurden dazu aus dem Knochenmark von je 5 gesunden Schafen und Pferden isoliert, bis zur Passage 4 (P4) expandiert und schließlich mit den verschiedenen SPIO-Produkten markiert. Unmarkierte MSC der gleichen Tiere dienten zur Kontrolle. Proliferationsvermögen sowie tripotentes Differenzierungspotential wurden in vitro untersucht. Zur Evaluierung von Markierungsselektivität und -effizienz der SPIO-Produkte wurden die MSC ab der P4 bis zur P7 wöchentlich passagiert. Ein semiquantitatives histologisches Auswertungssystem basierend auf der Preußisch Blau-Färbung sowie T2*w-GRE-Sequenzen an einem 0,5T-MRT-System wurden zur Evaluierung genutzt. Markierungsselektivität bezeichnete die intra- oder extrazelluläre Lokalisation der SPIO-Partikel. Markierungseffizienz beschrieb die Menge intrazellulär vorhandener SPIO-Partikel. Es wurde gezeigt, dass sich ovine und equine MSC mit allen 3 untersuchten SPIO-Produkten erfolgreich markieren ließen. Die Ergebnisse der in vitro-Untersuchungen ergaben keine Unterschiede zwischen SPIO-markierten und unmarkierten MSC hinsichtlich des Proliferationsvermögens, der adipogenen oder osteogenen Differenzierungsfähigkeit. Jedoch wurde eine deutliche Verminderung des chondrogenen Differenzierungspotentials SPIO-markierter MSC beobachtet, welche von der Menge intrazellulär vorhandener SPIO-Partikel und somit von der Markierungseffizienz abhängig war. Zum Zeitpunkt der initialen Markierung konnte nur Molday ION Rhodamine B™ eine selektive und effiziente Zellmarkierung gewährleisten. Mit Endorem™ konnte eine selektive, jedoch keine ausreichend effiziente Zellmarkierung erreicht werden. Resovist® dagegen bewirkte zwar eine effiziente, aber sehr unselektive initiale Zellmarkierung: Mittels Preußisch Blau-Färbung wurde gezeigt, dass große Mengen von SPIO-Partikeln nur extrazellulär anhefteten. Die 3 verschiedenen SPIO-Produkte führten weiterhin zu unterschiedlich starken hypointensen MRT-Signalen der markierten MSC, welche im Verlauf der 3-wöchigen Versuchsdauer bei allen 3 Produkten stetig abnahmen. Unmarkierte MSC waren isointens, also mittels MRT nicht darstellbar und daher nicht nachverfolgbar. Stets verursachten Resovist®-markierte MSC das stärkste hypointense MRT-Signal, gefolgt von Molday ION Rhodamine B™ und Endorem™. Resovist®-markierte MSC konnten mittels MRT bei beiden Spezies über den längsten Zeitraum nachverfolgt werden (ovine MSC bis 16 Tage, equine MSC bis 23 Tage nach Markierung). Aufgrund der exzellenten initialen Markierungseigenschaften (hohe Markierungsselektivität und –effizienz sowie gute Nachverfolgbarkeit) eignet sich Molday ION Rhodamine B™ besonders gut für die SPIO-Markierung von MSC zur Nachverfolgung mittels MRT. Molday ION Rhodamine B™ verspricht somit eine erfolgreiche Anwendung in einem in vivo-Versuch zur magnetresonsztomographischen Nachverfolgung von MSC nach Applikation in arthrotische Gelenke. / Mesenchymal stem cells (MSC) are already used in clinical studies for treatment of different diseases. However, their mechanism of action and fate after application are still not fully understood. In vivo tracking of labeled MSC via magnetic resonance imaging (MRI) is a possible method to achive further knowledge. For this purpose MSC can be labelled with superparamagnetic iron oxide (SPIO) particles. For this study 3 different SPIO products were employed for labelling of ovine and equine MSC: Endorem™, Resovist®,, and Molday ION Rhodamine B™. The products were compared in terms of their influence on biologic behaviour of the MSC, their labelling efficiency, and selectivity. Furthermore, product specific magnetic resonance traceability of SPIO labelled MSC was evaluated. Final aim was the selection of the most suitable SPIO product to be used in an in vivo large animal study employing MRI tracking of SPIO labelled MSC after application into osteoarthritic joints. MSC therefore, were isolated from bone marrow of each 5 healthy sheep and horses, expanded up to passage 4 (p4), and labelled by the different SPIO products. Unlabelled MSC from the same animals served as control. Proliferation potential and tripotent differentiation capacities were assessed in vitro. For evaluation of labelling selectivity and efficiency of the SPIO products MSC were passaged weekly from p4 up to p7. Semiquantitative histological scoring based on Prussian blue staining and images using T2*w GRE sequences in a 0.5T MRI system were used. Labelling selectivity describes the intra- or extracellular localisation of the SPIO particles. Labelling efficiency describes the amount of intracellular SPIO particles. It was shown that ovine and equine MSC could be successfully labelled by all 3 evaluated SPIO products. The results of the in vitro experiments did not show differences between labelled and unlabelled MSC in terms of proliferation potential, adipogenic or osteogenic differentiation capacities. However, an inhibited chondrogenic differentiation capacity of SPIO labelled MSC was observed, which was dependend on the amount of intracellular SPIO particles and therefore, also on labelling efficiency. At the time of initial labelling, only Molday ION Rhodamine B™ showed selective and efficient cell labelling. With Endorem™ selective, but not efficient cell labelling was achieved. Resovist®, in contrast, caused efficient but very unselective initial cell labelling: By Prussian blue staining it was shown that large amounts of SPIO particles were attached extracellularly. These 3 different SPIO products led to variable hypointense MRI signals of the labelled MSC which decreased in all 3 products during the 3 week study period. Unlabelled MSC were isointense, thus not visible, and therefore, not traceable using MRI. At every point of time, Resovist® labelled MSC resulted in the most hypointense MR signals, followed by Molday ION Rhodamine B™ and Endorem™. Resovist® labelled MSC were traced over the longest time span (ovine MSC until 16 days, equine MSC until 23 days post labelling). Due to excellent initial labelling properties (high labelling efficiency and selectivity, good traceability) Molday ION Rhodamine B™ suits best for SPIO labelling of MSC to be tracked by MRI. Molday ION Rhodamine B™ therefore, promises a successful use in an in vivo study using MRI for MSC tracking after application into osteoarthritic joints.

Mesenchymale Stammzellen (MSC) werden bereits in klinischen Studien zur Behandlung verschiedener Krankheiten eingesetzt. Über deren Wirkmechanismus und Verbleib nach Applikation ist jedoch noch wenig bekannt. Die in vivo-Nachverfolgung markierter MSC mittels Magnetresonanztomographie stellt eine mögliche Methode zur Erlangung weiterer Erkenntnisse dar. Zu diesem Zweck können die MSC mittels superparamagnetischen Eisenoxid (SPIO)-Partikeln markiert werden. In dieser Arbeit wurden 3 verschiedene SPIO-Produkte zur Markierung oviner und equiner MSC verwendet: Endorem™, Resovist® und Molday ION Rhodamine B™. Die Produkte wurden hinsichtlich ihrer Einflüsse auf die biologischen Eigenschaften der MSC, ihrer Markierungseffizienz und –selektivität verglichen. Desweiteren wurde die produktspezifische magnetresonanztomographische Nachverfolgbarkeit der SPIO-markierten MSC untersucht. Weiterführendes Ziel war die Selektion des am besten geeigneten SPIO-Produktes für die Verwendung in einem in vivo-Großtierversuch zur magnetresonanztomographischen Nachverfolgung SPIO-markierter MSC nach Applikation in arthrotische Gelenke. Die MSC wurden dazu aus dem Knochenmark von je 5 gesunden Schafen und Pferden isoliert, bis zur Passage 4 (P4) expandiert und schließlich mit den verschiedenen SPIO-Produkten markiert. Unmarkierte MSC der gleichen Tiere dienten zur Kontrolle. Proliferationsvermögen sowie tripotentes Differenzierungspotential wurden in vitro untersucht. Zur Evaluierung von Markierungsselektivität und -effizienz der SPIO-Produkte wurden die MSC ab der P4 bis zur P7 wöchentlich passagiert. Ein semiquantitatives histologisches Auswertungssystem basierend auf der Preußisch Blau-Färbung sowie T2*w-GRE-Sequenzen an einem 0,5T-MRT-System wurden zur Evaluierung genutzt. Markierungsselektivität bezeichnete die intra- oder extrazelluläre Lokalisation der SPIO-Partikel. Markierungseffizienz beschrieb die Menge intrazellulär vorhandener SPIO-Partikel. Es wurde gezeigt, dass sich ovine und equine MSC mit allen 3 untersuchten SPIO-Produkten erfolgreich markieren ließen. Die Ergebnisse der in vitro-Untersuchungen ergaben keine Unterschiede zwischen SPIO-markierten und unmarkierten MSC hinsichtlich des Proliferationsvermögens, der adipogenen oder osteogenen Differenzierungsfähigkeit. Jedoch wurde eine deutliche Verminderung des chondrogenen Differenzierungspotentials SPIO-markierter MSC beobachtet, welche von der Menge intrazellulär vorhandener SPIO-Partikel und somit von der Markierungseffizienz abhängig war. Zum Zeitpunkt der initialen Markierung konnte nur Molday ION Rhodamine B™ eine selektive und effiziente Zellmarkierung gewährleisten. Mit Endorem™ konnte eine selektive, jedoch keine ausreichend effiziente Zellmarkierung erreicht werden. Resovist® dagegen bewirkte zwar eine effiziente, aber sehr unselektive initiale Zellmarkierung: Mittels Preußisch Blau-Färbung wurde gezeigt, dass große Mengen von SPIO-Partikeln nur extrazellulär anhefteten. Die 3 verschiedenen SPIO-Produkte führten weiterhin zu unterschiedlich starken hypointensen MRT-Signalen der markierten MSC, welche im Verlauf der 3-wöchigen Versuchsdauer bei allen 3 Produkten stetig abnahmen. Unmarkierte MSC waren isointens, also mittels MRT nicht darstellbar und daher nicht nachverfolgbar. Stets verursachten Resovist®-markierte MSC das stärkste hypointense MRT-Signal, gefolgt von Molday ION Rhodamine B™ und Endorem™. Resovist®-markierte MSC konnten mittels MRT bei beiden Spezies über den längsten Zeitraum nachverfolgt werden (ovine MSC bis 16 Tage, equine MSC bis 23 Tage nach Markierung). Aufgrund der exzellenten initialen Markierungseigenschaften (hohe Markierungsselektivität und –effizienz sowie gute Nachverfolgbarkeit) eignet sich Molday ION Rhodamine B™ besonders gut für die SPIO-Markierung von MSC zur Nachverfolgung mittels MRT. Molday ION Rhodamine B™ verspricht somit eine erfolgreiche Anwendung in einem in vivo-Versuch zur magnetresonsztomographischen Nachverfolgung von MSC nach Applikation in arthrotische Gelenke. / Mesenchymal stem cells (MSC) are already used in clinical studies for treatment of different diseases. However, their mechanism of action and fate after application are still not fully understood. In vivo tracking of labeled MSC via magnetic resonance imaging (MRI) is a possible method to achive further knowledge. For this purpose MSC can be labelled with superparamagnetic iron oxide (SPIO) particles. For this study 3 different SPIO products were employed for labelling of ovine and equine MSC: Endorem™, Resovist®,, and Molday ION Rhodamine B™. The products were compared in terms of their influence on biologic behaviour of the MSC, their labelling efficiency, and selectivity. Furthermore, product specific magnetic resonance traceability of SPIO labelled MSC was evaluated. Final aim was the selection of the most suitable SPIO product to be used in an in vivo large animal study employing MRI tracking of SPIO labelled MSC after application into osteoarthritic joints. MSC therefore, were isolated from bone marrow of each 5 healthy sheep and horses, expanded up to passage 4 (p4), and labelled by the different SPIO products. Unlabelled MSC from the same animals served as control. Proliferation potential and tripotent differentiation capacities were assessed in vitro. For evaluation of labelling selectivity and efficiency of the SPIO products MSC were passaged weekly from p4 up to p7. Semiquantitative histological scoring based on Prussian blue staining and images using T2*w GRE sequences in a 0.5T MRI system were used. Labelling selectivity describes the intra- or extracellular localisation of the SPIO particles. Labelling efficiency describes the amount of intracellular SPIO particles. It was shown that ovine and equine MSC could be successfully labelled by all 3 evaluated SPIO products. The results of the in vitro experiments did not show differences between labelled and unlabelled MSC in terms of proliferation potential, adipogenic or osteogenic differentiation capacities. However, an inhibited chondrogenic differentiation capacity of SPIO labelled MSC was observed, which was dependend on the amount of intracellular SPIO particles and therefore, also on labelling efficiency. At the time of initial labelling, only Molday ION Rhodamine B™ showed selective and efficient cell labelling. With Endorem™ selective, but not efficient cell labelling was achieved. Resovist®, in contrast, caused efficient but very unselective initial cell labelling: By Prussian blue staining it was shown that large amounts of SPIO particles were attached extracellularly. These 3 different SPIO products led to variable hypointense MRI signals of the labelled MSC which decreased in all 3 products during the 3 week study period. Unlabelled MSC were isointense, thus not visible, and therefore, not traceable using MRI. At every point of time, Resovist® labelled MSC resulted in the most hypointense MR signals, followed by Molday ION Rhodamine B™ and Endorem™. Resovist® labelled MSC were traced over the longest time span (ovine MSC until 16 days, equine MSC until 23 days post labelling). Due to excellent initial labelling properties (high labelling efficiency and selectivity, good traceability) Molday ION Rhodamine B™ suits best for SPIO labelling of MSC to be tracked by MRI. Molday ION Rhodamine B™ therefore, promises a successful use in an in vivo study using MRI for MSC tracking after application into osteoarthritic joints.

Des nanoparticules d’oxydes de fer superparamagnétiques (SPIONs) PEGylées ont servi de plateforme pour la formulation de nanovecteurs théragnostiques pour la délivrance d’un agent anticancéreux, la doxorubicine (DOX). Le chargement de la DOX sur les nanovecteurs à l’aide d’un complexe avec l’ion fer (II) a été optimisé. Ce complexe se dissocie en milieu acide, typique des compartiments intracellulaires. La spectroscopie Raman exaltée de surface (SERS) a confirmé que les nanovecteurs libèrent la DOX sous forme non complexée. La cytotoxicité in vitro induite par la libération de la DOX a été évaluée sur différentes lignées cellulaires de cancer du sein, et comparée à celle de la DOX en solution. Les voies d’internalisation des nanovecteurs ont été explorées en microscopie électronique en transmission (MET), et le devenir intracellulaire de la DOX a été suivi en imagerie confocale multispectrale (ICMS). Enfin, un protocole thérapeutique in vivo chez la souris tumorisée a permis d’évaluer la capacité de la nanoformulation à limiter la croissance tumorale, la possibilité d’un ciblage magnétique, et la réduction des effets secondaires induits par la DOX. / PEGylated superparamagnetic iron oxide nanoparticles (SPIONs) were used as a platform to build theranostic nanovectors for the delivery of an anticancer drug, doxorubicin (DOX). The DOX loading on nanocarriers via a DOX-iron (II) complex was optimized. The complex dissociates at low pH, typical of intracellular compartments. Surface enhanced Raman scattering (SERS) confirmed that the nanovectors released DOX under free form. In vitro cytotoxicity due to DOX loaded on nanocarriers was performed on different breast cancer cells, and compared to that of DOX in solution. Internalization pathways of nanovectors were explored with transmission electron microscopy (TEM), and intracellular fate of DOX was monitored by confocal spectral imaging (CSI). To finish, a therapeutical protocol was performed on tumorized mice, in order to evaluate the efficacy of the nanoformulation on tumor reduction, the possibility of magnetic targeting, and the decrease of side effects induced by DOX.

Ce travail de thèse s'inscrit dans le cadre d'une collaboration avec le groupe Guerbet. Il visait à caractériser la lésion qui fait suite à un accident vasculaire cérébral (AVC) ischémique en imagerie par résonance magnétique (IRM) grâce à des agents de contraste novateurs. Guerbet et leurs collaborateurs ont développés des USPIO ciblés (ultrasmall superparamagnetic iron oxide), particules de fer couplées à des peptides reconnaissant spécifiquement un biomarqueur. Dans un modèle d’ischémie cérébrale avec reperfusion réalisé chez la souris, nous avons recherché la capacité de ces agents à caractériser la lésion d’une part en terme de type de mort cellulaire par le ciblage de la phosphatidylsérine (PS), marqueur cellulaire externalisé au cours de l’apoptose, et d’autre part en terme de déficit vasculaire par le ciblage de VCAM-1, molécule d’adhésion impliquée dans le processus inflammatoire. En ce qui concerne l’apoptose, nous avons tout d’abord montré par immunohistochimie l’expression de caspase-3 active, marqueur apoptotique, dès 6 heures et jusqu’à 72 heures après l’ischémie. Cependant, en IRM, l’utilisation d’USPIO ciblant la PS (le P03234 et le P03675) n’a pas permis la détection du phénomène apoptotique. Actuellement d’autres agents de contraste de ce type sont en cours de développement chez Guerbet. En ce qui concerne l’inflammation vasculaire, l’étude de l’expression de VCAM-1 par immunohistochimie a montré l’apparition d’un marquage dès 6 heures après l’ischémie avec un maximum à 24 heures. L’utilisation d’un USPIO-VCAM-1 (le P03011) a permis de mettre en évidence sur les images IRM des zones d’hypointensités dans la lésion, ce qui correspond à la présence de particules de fer. L'analyse histologique de ces cerveaux a montré une colocalisation de l’USPIO avec sa cible VCAM-1, ce qui établit la preuve de concept. Ces travaux ont permis mettre en évidence la capacité d’USPIO développés par Guerbet à cibler des marqueurs biologiques, notamment VCAM-1, à la suite d’une ischémie cérébrale. Ceci suggère que ce type d’agent de contraste pourrait être un bon outil clinique pour la caractérisation de la lésion ischémique chez les patients victimes d’AVC. / This work is a collaboration with Guerbet group. It aimed to characterize the lesion that follows an ischemic stroke with magnetic resonance imaging (MRI) by innovative contrast agents. Guerbet developped targeted USPIO (ultrasmall superparamagnetic iron oxide), which are iron particles coupled to peptides which specifically bind a biomarker. In a mouse model of cerebral ischemia-reperfusion, we studied the capacity of these agents to characterize the lesion on the one hand in terms of cellular death by targeting phosphatidylserin (PS), a cellular marker externalized during apoptosis, and on the other hand in terms of vascular deficit by targeting VCAM-1, an adhesion molecule implied in the inflammatory process. Concerning apoptosis, we showed by immunohistochemistry the expression of active caspase-3, an apoptotic marker, between 6 and 72 hours after ischemia. Nevertheless on MRI, the use of USPIO targeting PS (both P03234 and P03675) did not allow us to detect the apoptotic phenomenon. Currently, other PS-targeted contrast agents are developed by Guerbet. Concerning vascular inflammation, the study of VCAM-1 by immunohistochemistry showed an up-regulated expression 6 hours after ischaemia which reached a maximum at 24 hours. VCAM-1-USPIO (P03011) induced a decrease of the MRI signal appearing as hypointense foci in the lesion, which correspond to iron particles. The histological analysis of these brains showed a colocalisation of the USPIO with its target VCAM-1, which establishes the proof of concept. This work showed the capacity of USPIO developed by Guerbet to target biological markers, particularly VCAM-1, following cerebral ischemia. This suggests that this kind of contrast agent could be a good clinical tool to characterize the ischemic lesion in patients suffering from stroke.

La greffe d'îlots de Langerhans permet de traiter le diabète de type 1 en restituant une insuline-sécrétion. La moitié des patients reprend l'insuline dans les 5 ans. Cette perte de fonction s'explique par l'absence d'outils de monitoring. Le but de notre travail était de déterminer l'efficacité de l'IRM à diagnostiquer un rejet de greffe, et d'évaluer l'intérêt du monitoring cellulaire chez les patients.Imagerie IRM chez le ratMéthodes : Des îlots syngéniques, allogéniques ou xénogéniques ont été greffés par voie intra-portale à des rats diabétiques après marquage avec une nanoparticule de fer (ferucarbotran). Les IRM étaient réalisées dans une IRM clinique 3T.Résultats : La décroissance du signal était différente suivant les 3 types de greffes. Le signal IRM des greffes allogéniques était significativement plus bas à J4 alors que la glycémie était normale. En prenant un seuil de 84% à J4, l'IRM permet d'obtenir une sensibilité de 91% et une spécificité de 70% Innnuno-monitoring cellulaireMéthodes : Des réactions lymphocytaires mixtes étaient réalisées entre les PBMC des patients greffés, et les splénocytes des donneurs. La réaction immunitaire était évaluée par la sécrétion d'IFNy (ELISpot), par la prolifération cellulaire (cytométrie du flux du Ki67), et par le dosage des cytokines (Bioplex). Le résultat était corrélé à la fonction du greffon évaluée par le (3-score).Résultats : Les patients avec une mauvaise fonction montraient une plus grande réactivité anti-donneur avec l'ELISpot IFNy (p=0,007, r=-0,50) et l'index de prolifération (p=0,006, r=-0,51). Les patients avec une mauvaise fonction avaient des taux d'IFNy, IL-5 et IL-17 plus élevés. / Langerhans islet transplantation allows curingtype 1 diabetes by restoring an endogenous insulin secretion. Halfof patients will resume insulin withinyears. This loss of function may be explained by the lack of monitoring tools able to diagnose an ongoing graft failure. The aims of our work were toevaluate the efficiency of MRI to diagnose islet graft rejection, and to assess the feasibility of immune cellular monitoring in transplanted patients.MRI in the rat mortelMethods: Syngeneic, allogeneic and xenogeneic islets were transplanted intra-portally to diabetic rats after labeling with superparamagnetic ironoxide nanoparticles (ferucarbotran). Images were acquired on a clinical 3T MRI scanner.Results: The signal decreasing was different between the 3 types of transplantations. At day 4, the MRI signal in allogeneic group was significantlylower while glycaemia remained normal. With a cut-off value of 84% at day 4, sensitivity of 91% and specificity of 70% were obtained.Cellular immune monitoringMethods: Mixed lymphocyte cultures were performed with peripheral blood mononuclear cells from recipients and splenocytes from donors. Immunereactivity was assessed by the release of IFNy (ELISpot), cell prolifération (flow cytometry of Ki67), and cytokine quantification (Bioplex). Theresults were correlated to the islet graft function assessed by (5-score.Results: Patients with low islet function showed higher cellular reactivity against donor cells assessed by ELISpot IFNy ((p=0,007, r=-0,50) andproliferation index (p=0,006, r=-0,51). Patients with low graft function had higher levels of IFNy, IL-5 and 1L-17.

Safety concerns arising from cytotoxic behavior of nanoparticles (NPs) in complex biological environment remain the main problem limiting NPs application in biomedicine. In this study, we have investigated cytotoxicity of NPs with different composition, shape and size, namely SiO2 NPs (SiNPs, 7-14 nm), superparamagnetic iron oxide NPs (SPIONs, 8 nm) and carboxylated multiwalled carbon nanotubes (CNTCOOHs, diameter: 60-100 nm, length: 1-2 μm). Cytotoxicity was evaluated with newly designed screening assay capable to simultaneously assess activity of cell dehydrogenases, activity of lactate dehydrogenase (LDH) released from cells into environment and number of intact cell nuclei and apoptotic bodies in human umbilical vein endothelial cell (HUVEC) culture growing in the very same well of the 96-well plate. Aforementioned attributes were subsequently utilized to obtain information about cell viability and necrotic and apoptotic aspects of cell death. Results from this "three-in-one" cell death screening (CDS) assay showed that SiNPs and CNTCOOHs evoked pronounced cytotoxic effect demonstrated as decrease of cell viability and development of apoptotic bodies formation. In contrast to this, SPIONs induced only mild cytotoxicity. Moreover, SiNPs impaired cell membrane leading to increased LDH release...